COMMUNIQUÉS West-GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences
06/08/2024
SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in August: 2024 Wedbush PacGrow [...]
ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024
06/08/2024
LOS ANGELES, Aug. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today [...]
STERIS Announces Financial Results for Fiscal 2025 First Quarter
06/08/2024
Total revenue from continuing operations increased 8%; constant currency organic revenue grew 6% As reported EPS from continuing operations increased to $1.41; adjusted EPS increased to $2.03 Fiscal 2025 outlook [...]
UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates
06/08/2024
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported [...]
Cellectis publie ses résultats financiers du deuxième trimestre 2024
06/08/2024
Statuts de médicament orphelin et de médicament pour une maladie pédiatrique rare accordés par la FDA et statut de médicament orphelin accordé par la Commission européenne à UCART22 pour le traitement de la leucémie [...]
Cellectis Provides Financial Results for the Second Quarter 2024
06/08/2024
ODD and RPDD granted by the FDA and ODD granted by the European Commission to UCART22 for the treatment of ALL ODD granted by the FDA to CLLS52 (alemtuzumab) for ALL treatment Cash position of $273 million as of June 30 [...]
Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
06/08/2024
Late-stage pipeline program, Anaphylm™ (epinephrine) Sublingual Film, remains on track for a near-term New Drug Application (NDA) submission to the FDA Expanded sales coverage for Libervant™ (diazepam) Buccal Film for [...]
Globus Medical Reports Second Quarter 2024 Results
06/08/2024
AUDUBON, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2024. Worldwide net [...]
CooperCompanies Announces Release Date for Third Quarter 2024
06/08/2024
SAN RAMON, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO) today announced it will report third quarter 2024 financial results on Wednesday, August 28, 2024, at 4:15 PM ET. Following the release [...]
Certara Reports Second Quarter 2024 Financial Results
06/08/2024
Reiterates Full Year 2024 Financial Guidance RADNOR, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the [...]
Supernus Announces Second Quarter 2024 Financial Results
06/08/2024
Net sales of Qelbree ® increased 92% in the second quarter of 2024, compared to the same period in 2023. $59.4 million and $104.5 million of net sales in the second quarter and first six months of 2024, respectively. [...]
Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights
06/08/2024
Announced 3 new programs, including genetic disease programs in vascular malformations, Fabry disease, as well as precision oncology program with NRAS-specific inhibitor Initiated global clinical trial collaboration [...]
Trinity Biotech Obtains an Extension to Demonstrate Compliance With Nasdaq Listing Requirements
06/08/2024
DUBLIN, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, [...]
MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance
06/08/2024
MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance ROCKVILLE, MD, August 6, 2024 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused [...]
Nyxoah Reports Second Quarter and First Half 2024 Financial and Operating Results
06/08/2024
REGULATED INFORMATION Nyxoah Reports Second Quarter and First Half 2024 Financial and Operating Results FDA regulatory submission complete, U.S. approval on track for end of 2024 U.S. commercial launch fully funded with [...]
Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Deuxième Trimestre et Premier Semestre 2024
06/08/2024
INFORMATIONS RÉGLEMENTÉES Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Deuxième Trimestre et Premier Semestre 2024 Soumission réglementaire auprès de la complétée, l'approbation aux États-Unis est [...]
Nanox to Report Second Quarter and Financial Results on August 20, 2024
06/08/2024
PETACH TIKVA, Israel, Aug. 06, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial [...]
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
06/08/2024
- Enrollment progressing well across all arms in the IMM-1-104 Phase 2a Trial, with Initial Data from Multiple Arms Expected in 2H 2024 - - Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic [...]
MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance
06/08/2024
ROCKVILLE, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and [...]

Pages